December 20, 2016 GenSight Biologics reports sustained visual acuity gain at 78 weeks in its Phase I/II Study with GS010 for the treatment of Leber’s Hereditary Optic Neuropathy (LHON)
December 16, 2016 Cerenis Therapeutics Receives FDA IND Approval to Begin Studies with CER-209 in NAFLD and NASH
December 06, 2016 Altimmune Announces Acceptance of HepTcell Abstract for Presentation at BSI/NVVI Congress 2016
December 06, 2016 Nordic Nanovector: Betalutin® in combination with rituximab demonstrates synergistic anti-tumour effect in preclinical non-Hodgkin lymphoma model